Sodium-Glucose Cotransporter-2 Inhibitors: Heart Failure and Renal Protection Indications

被引：2
|
作者：
El Hussein, Mohamed Toufic [1 ,2 ,3 ]
Bell, Nicole [4 ]
机构：
[1] Mt Royal Univ Calgary, Fac Hlth Community & Educ, Sch Nursing & Midwifery, Calgary, AB, Canada
[2] Univ Calgary Calgary, Fac Nursing, Calgary, AB, Canada
[3] Rockyview Gen Hosp Calgary, Coronary Care Unit, Med Cardiol, Calgary, AB, Canada
[4] Mt Royal Univ, Calgary, AB, Canada
来源：
JNP- THE JOURNAL FOR NURSE PRACTITIONERS | 2022年 / 18卷 / 02期
关键词：
heart failure; renal failure; sodium-glucose cotransporter-2 inhibitors; type; 2; diabetes; CARDIOVASCULAR EVENTS; EMPAGLIFLOZIN; RATIONALE; DESIGN; RISK;
D O I：
10.1016/j.nurpra.2021.09.002
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are a class of oral antihyperglycemic drugs recently added to clinical practice guidelines to manage type 2 diabetes mellitus (T2DM). Recent clinical trials have established significant benefits in using SGLT-2is to treat both heart failure and renal disease. This article aims to explain the clinical benefits of inhibiting sodium-glucose cotransporter-2 proteins in patients with T2DM, renal disease, and heart failure. These authors also seek to guide nurse practitioners in prescribing SGLT-2is. Evidence-based guidance for nurse practitioners to treat T2DM, heart failure, and renal disease is likely to improve patients' clinical outcomes and decrease associated morbidities. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码：179 / 184
页数：6
相关论文
共 50 条
  • [21] Sodium-glucose cotransporter-2 inhibitors for heart failure: time is up for indulging in wishful thinking
    Alvarez-Garcia, Jesus
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (07) : 1010 - 1011
  • [22] Expediting the Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure-There Is No Time for Delay
    Fonarow, Gregg C.
    Yancy, Clyde W.
    JAMA CARDIOLOGY, 2021, 6 (05) : 507 - 508
  • [23] Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure
    Zhou, Lili
    Yang, Yuanyuan
    Han, Weixing
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (10) : 10887 - 10895
  • [24] Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Racial Differences and a Potential for Reducing Disparities
    Morris, Alanna A.
    Testani, Jeffrey M.
    Butler, Javed
    CIRCULATION, 2021, 143 (24) : 2329 - 2331
  • [25] Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis
    Anan, Go
    Kikuchi, Daisuke
    Hirose, Takuo
    Ito, Hiroki
    Nakayama, Shingo
    Mori, Takefumi
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (04): : 925 - 928
  • [26] Erythrocytosis induced by sodium-glucose cotransporter-2 inhibitors
    Chin-Yee, Benjamin
    Solh, Ziad
    Hsia, Cyrus
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2020, 192 (42) : E1271 - E1271
  • [27] Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
    Heerspink, Hiddo J. L.
    Kosiborod, Mikhail
    Inzucchi, Silvio E.
    Cherney, David Z. I.
    KIDNEY INTERNATIONAL, 2018, 94 (01) : 26 - 39
  • [28] Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure
    Docherty, Kieran F.
    Petrie, Mark C.
    HEART, 2022, 108 (04) : 312 - 320
  • [29] Sodium-glucose cotransporter 2 inhibitors for the management of heart failure
    Nouel, Ana
    Winter, Jose Luis
    Sepulveda, Luis
    REVISTA MEDICA DE CHILE, 2022, 150 (12) : 1647 - 1654
  • [30] Heart failure prevention with sodium-glucose cotransporter 2 inhibitors
    Khan, Muhammad Shahzeb
    Butler, Javed
    JOURNAL OF DIABETES, 2019, 11 (07) : 601 - 604
12345